Forbion mitigates risk by repeatedly backing the same successful management teams. After an exit, they often fund that team's next venture. This "founder recycling" strategy leverages proven operational chemistry and execution ability, as seen with the teams behind Gyroscope, IOLOS, and Ferdiva.

Beyond the thesis, first-time biotech funds must explicitly align with LPs on the 6-to-9-year journey from seed to exit. Daniel Fero stresses finding LPs who understand their capital will be locked up for a long duration, unlike in crossover funds with shorter horizons. This "psychological fit" on capital flow expectations is crucial for a stable fund.

The strongest signal a VC can receive is when a founder they've backed asks to become a Limited Partner, especially after an exit. It proves the VC's value far exceeded the capital provided, demonstrating deep trust and authentic partnership.

While a first fund is raised on a compelling vision, raising a second requires demonstrating institutional maturity. LPs shift from underwriting a founder's promise to underwriting a firm's ability to be "consistently excellent." The narrative must evolve to highlight repeatable processes, refined decision frameworks, and a scalable organizational structure.

Securing an initial commitment from a well-respected LP, especially one known for rigorous due diligence, is more than just capital. It acts as a powerful signal to the rest of the market that your firm has been thoroughly vetted, making it easier to attract subsequent investors who can leverage that initial diligence.

The initial capital for a new fund-of-funds doesn't come from cold outreach to institutions. The process mirrors an emerging VC's first fundraise, relying on a personal network of operators, VCs, and high-net-worth individuals who already believe in the founder. The strategy is to work the existing network outward, not pitch institutions from day one.

Repro Novo's co-founders invested their own money for the costly process of finding and negotiating assets. This allowed them to secure a promising candidate before approaching institutional investors, demonstrating strong conviction and de-risking the initial investment for VCs.

Instead of relying solely on traditional LPs, Vi Ventures actively brings in families affected by autoimmune diseases as for-profit investors. This model creates a community of highly motivated stakeholders, fostering accountability and a direct connection to the patient experience, while still maintaining market-rate return objectives.

A clever strategy for first-time fund managers is to raise smaller checks from a large number of operators and domain experts. While harder to execute, this turns the LP base into a powerful, built-in expert network for diligence and support, converting a fundraising challenge into a strategic asset.